CD8A and cancer: The heterologous prime-boost vaccination strategy has been investigated and was shown to achieve the best results in terms of the induction of long-lived protective CD8+ T cells [3] and is thought to be suitable at improving treatment efficacy while counteracting tumor immune escape in cancer therapy [4].